Meta-Analysis of Microsomal Epoxide Hydrolase Gene Polymorphism and Risk of Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zhong, Jian Hong ^a   Xiang, Bang De ^a   Ma, Liang ^a   You, Xue Mei ^a   Li, Le Qun ^a   Xie, Gui Sheng ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HISTIDINE; TYROSINE;

ALLELE; ALLELIC CONTRAST; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC PARAMETERS; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; HOMOZYGOTE; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MICROSOMAL EPOXIDE HYDROLASE GENE; RECESSIVE INHERITANCE; RISK FACTOR; SYSTEMATIC REVIEW;

CARCINOMA, HEPATOCELLULAR; EPOXIDE HYDROLASES; ETHNIC GROUPS; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 84874531243     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057064     Document Type: Article

References (45)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Nordenstedt H, White DL, El-Serag HB, (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42Suppl 3: S206-214.
3. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, et al. (2004) The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39: 211-219.
4. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Pérez R, et al. (2003) Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37: 520-527.
5. Coleman WB, (2003) Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3: 573-588.
6. Newman JW, Morisseau C, Hammock BD, (2005) Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 44: 1-51.
7. Fretland AJ, Omiecinski CJ, (2000) Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact 129: 41-59.
8. Shou M, Gonzalez FJ, Gelboin HV, (1996) Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase. Biochemistry 35: 15807-813.
9. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ, (1994) Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3: 421-428.
10. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, et al. (1995) Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A 92: 2384-2387.
11. Shen F, Hu Y, (1997) Association between the gene polymorphism of epoxide hydrolase and the susceptibility to primary hepatocellular carcinoma. Chin J Med Genet 14: 96-98.
12. Wong NA, Rae F, Bathgate A, Smith CA, Harrison DJ, (2000) Polymorphisms of the gene for microsomal epoxide hydrolase and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a Caucasian population. Toxicol Lett 115: 17-22.
13. Tiemersma EW, Omer RE, Bunschoten A, van't Veer P, Kok FJ, et al. (2001) Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 10: 785-791.
14. Sonzogni L, Silvestri L, De Silvestri A, Gritti C, Foti L, et al. (2002) Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 36: 195-201.
15. McGlynn KA, Hunter K, LeVoyer T, Roush J, Wise P, et al. (2003) Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 63: 4594-4601.
16. Cao YY, Bian JC, Jiang F, Zhang ZM, Wang QM, et al. (2004) Association between the genetic polymorphism of epoxide hydrolase and the genetic susceptibility to primary liver cancer. Fudan University Journal of Medical Sciences 31: 363-367.
17. Kirk GD, Turner PC, Gong Y, Lesi OA, Mendy M, et al. (2005) Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomarkers Prev 14: 373-379.
18. Long XD, Ma Y, Wei YP, Deng ZL, (2006) The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res 36: 48-55.
19. Kiran M, Chawla YK, Kaur J, (2008) Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. DNA Cell Biol 27: 687-694.
20. He SJ, Gu YY, Lin WZ, Zeng XY, Liao ZH, (2008) Polymorphism of microsomal epoxide hydrolase and susceptibility to primary hepatocellular carcinoma. Tumor 28: 125-128.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
22. Ioannidis JP, Trikalinos TA, (2007) An exploratory test for an excess of significant findings. Clin Trials 4: 245-253.
23. Kiran M, Chawla YK, Jain M, Kaur J, (2009) Haplotypes of microsomal epoxide hydrolase and x-ray cross-complementing group 1 genes in Indian hepatocellular carcinoma patients. DNA Cell Biol 28: 573-577.
24. Rahat B, Kiran M, Saxena R, Chawla YK, Sharma RR, et al. (2012) Microsomal Epoxide Hydrolase Polymorphisms and Haplotypes as Determinants of Hepatitis B Virusand Hepatitis C Virus-related Liver Disease in Indian Population. J Clin Exp Hepatol 2: 104-111.
25. Llovet JM, Bruix J, (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
26. Koutros S, Andreotti G, Berndt SI, Hughes BK, Lubin JH, et al. (2011) Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer. Pharmacogenet Genomics 21: 615-623.
27. Goode EL, White KL, Vierkant RA, Phelan CM, Cunningham JM, et al. (2011) Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk. Mol Carcinog 50: 397-402.
28. Pinarbasi H, Silig Y, Pinarbasi E, (2010) Microsomal epoxide hydrolase polymorphisms. Mol Med Report 3: 723-727.
29. Ghattas MH, Amer MA (2012) Possible role of microsomal epoxide hydrolase gene polymorphism as a risk factor for developing insulin resistance and type 2 diabetes mellitus. Endocrine [Epub ahead of print].
30. Bhaskar LV, Thangaraj K, Patel M, Shah AM, Gopal K, et al. (2012) EPHX1 Gene Polymorphisms in Alcohol Dependence and their Distribution among the Indian Populations. Am J Drug Alcohol Abuse [Epub ahead of print].
31. Chen CZ, Wang RH, Lee CH, Lin CC, Chang HY, et al. (2011) Polymorphism of microsomal epoxide hydrolase is associated with chronic obstructive pulmonary disease and bronchodilator response. J Formos Med Assoc 110: 685-689.
32. Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S, et al. (2002) Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers 7: 230-241.
33. Li X, Hu Z, Qu X, Zhu J, Li L, et al. (2011) Putative EPHX1 enzyme activity is related with risk of lung and upper aerodigestive tract cancers: a comprehensive meta-analysis. PLoS One 6: e14749.
34. Dura P, Bregitha CV, Te Morsche RH, Roelofs HM, Kristinsson JO, et al. (2012) EPHX1 polymorphisms do not modify esophageal carcinoma susceptibility in Dutch Caucasians. Oncol Rep 27: 1710-1716.
35. Nisa H, Budhathoki S, Morita M, Toyomura K, Nagano J, et al. (2012) Microsomal epoxide hydrolase polymorphisms, cigarette smoking, and risk of colorectal cancer: The Fukuoka Colorectal Cancer Study. Mol Carcinog [Epub ahead of print].
36. Zhao ZQ, Guan QK, Yang FY, Zhao P, Zhou B, et al. (2012) System review and metaanalysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk. Tumour Biol 33(2): 523-535.
37. Baxter SW, Choong DY, Campbell IG, (2002) Microsomal epoxide hydrolase polymorphism and susceptibility to ovarian cancer. Cancer Lett 177: 75-81.
38. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y, (2006) EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology 17: 89-99.
39. Wild CP, Jiang YZ, Allen SJ, Jansen LA, Hall AJ, et al. (1990) Aflatoxin-albumin adducts in human sera from different regions of the world. Carcinogenesis 11: 2271-2274.
40. Wild CP, Hudson GJ, Sabbioni G, Chapot B, Hall AJ, et al. (1992) Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1: 229-234.
41. Vall Mayans M, Hall AJ, Inskip HM, Chotard J, Lindsay SW, et al. (1990) Risk factors for transmission of hepatitis B virus to Gambian children. Lancet 336: 1107-1109.
42. Kelly EJ, Erickson KE, Sengstag C, Eaton DL, (2002) Expression of human microsomal epoxide hydrolase in Saccharomyces cerevisiae reveals a functional role in aflatoxin B1 detoxification. Toxicol Sci 65: 35-42.
43. Zhong JH, You XM, Gong WF, Ma L, Zhang Y, et al. (2012) Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One 7: e32159.
44. Qin H, Liu B, Shi T, Liu Y, Sun Y, et al. (2010) Tumour necrosis factor-alpha polymorphisms and hepatocellular carcinoma: a meta-analysis. J Int Med Res 38: 760-768.
45. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP, (2005) Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med 2: e334.